Kevin Feeley - 09 Jul 2025 Form 4 Insider Report for GeneDx Holdings Corp. (WGS)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Bridget Brown, Attorney-in-Fact
Issuer symbol
WGS
Transactions as of
09 Jul 2025
Net transactions value
-$450,180
Form type
4
Filing time
11 Jul 2025, 16:04:11 UTC
Previous filing
03 Jul 2025
Next filing
31 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Feeley Kevin CHIEF FINANCIAL OFFICER C/O GENEDX HOLDINGS CORP., 333 LUDLOW ST, NORTH TOWER, 6TH FLOOR, STAMFORD /s/ Bridget Brown, Attorney-in-Fact 11 Jul 2025 0001944119

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WGS Class A Common Stock Options Exercise $40,674 +1,245 +17% $32.67 8,670 09 Jul 2025 Direct
transaction WGS Class A Common Stock Sale $490,854 -5,278 -61% $93.00 3,392 09 Jul 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WGS Employee Stock Option (Right to Buy) Options Exercise $0 -1,245 -17% $0.000000 6,228 09 Jul 2025 Common Stock 1,245 $32.67 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024.
F2 Following the reported sales and option exercise, in addition to the 3,392 shares of Class A common stock and the option to purchase up to 6,228 shares of Class A common stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned restricted stock units ("RSUs") representing contingent rights to receive up to an aggregate of 135,762 shares of Class A common stock and additional options to purchase up to an aggregate of 20,924 shares of Class A common stock, which RSUs and options vest according to their respective terms.
F3 6.25% vest in quarterly installments over the 4-year period commencing on December 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.